Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 19, 2022 4:17pm
171 Views
Post# 34835436

RE:No SP reaction to TH1902 good news

RE:No SP reaction to TH1902 good newsBecause it's the middle of the summer, because Thera is an old company with the reputation to be a strong underachiever, because Thera is coming out of nowhere in oncology with a technology developed at Universite du Quebec a Montreal (UQAM), not Harvard, finally, because on partial response will not spark real interest. It is not enough to be sure of anything, in fact, it is far from enough. Personnally I think it is proff of concept, that with the other signs of efficacy, but for a potential new investors not aware of all the details of this story, one partial response in phase Ia is lost in the noise.


TH1902 wrote: Anyone want to speculate why?  

I want to believe that we are under the radar and the story needs to be told but the non-response is somewhat disturbing to me.


<< Previous
Bullboard Posts
Next >>